In recent years, her team has focused on advancing a comprehensive Prostate Cancer Germline Initiative (NIH 508511) , which encompasses in-house sequencing, diagnostic services, and educational programs for both physicians and patients. This initiative underscores the critical significance of NCCN-recommended germline studies for high-risk prostate cancer patients. The next phase of this work involves transitioning to in-house somatic testing, which is currently in progress.

Dr. Anderson earned her M.D. from New York Medical College and completed her studies in Molecular Biology and Tumor Cytogenetics at MSKCC with Dr. Raju Chaganti.